Evotec SE
XETRA:EVT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Evotec SE
Current Portion of Long-Term Debt
Evotec SE
Current Portion of Long-Term Debt Peer Comparison
Competitive Current Portion of Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
E
|
Evotec SE
XETRA:EVT
|
Current Portion of Long-Term Debt
€154.8m
|
CAGR 3-Years
73%
|
CAGR 5-Years
18%
|
CAGR 10-Years
25%
|
Gerresheimer AG
XETRA:GXI
|
Current Portion of Long-Term Debt
€465.4m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
S
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
Current Portion of Long-Term Debt
€3.1m
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Evotec SE's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
154.8m
EUR
Based on the financial report for Mar 31, 2024, Evotec SE's Current Portion of Long-Term Debt amounts to 154.8m EUR.
What is Evotec SE's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
25%
Over the last year, the Current Portion of Long-Term Debt growth was 845%. The average annual Current Portion of Long-Term Debt growth rates for Evotec SE have been 73% over the past three years , 18% over the past five years , and 25% over the past ten years .